Therma Bright Adds $1,171,875 to Treasury Through Exercise of Warrants and Options
Toronto, Ontario--(Newsfile Corp. - January 29, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that in the past month, investors have exercised a total of 7,582,500 warrants and options to add $1,171,875 to the Company's treasury. With the addition of the $300,000, as previously reported in the press release on December 24th, 2020, the Company has added a total of $1,471,875 to the Company's treasury...
2021-01-29 8:42 AM EST
Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test
Toronto, Ontario--(Newsfile Corp. - January 25, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it has taken 100% control of the research and development, regulatory, manufacturing and commercialization of its saliva-based rapid antigen test. As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test. Therma Bright previously...
2021-01-25 6:30 AM EST
Therma Bright Reports Improved Accuracy For Its COVID-19 Rapid Saliva Antigen Test, CoviSafeTM, And Prepares For Prospective Studies
Toronto, Ontario--(Newsfile Corp. - January 18, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that the most recent results achieved with nanoComposix using banked human saliva samples and utilizing a CoviSafe™ prototype device indicate a test sensitivity of 86% and a specificity of 100% for Therma's CoviSafe™ rapid antigen test for detecting SARS-CoV-2 virus in saliva. As previously reported on...
2021-01-18 4:00 PM EST
Therma Bright Adds Veteran Manufacturing Expert to Advisory Team to Advance its Saliva-Based Rapid Antigen Test CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - January 15, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the appointment of Ian Levine to the advisory board to assist with future scaling for the manufacture of CoviSafe™. Mr. Levine will build the overall operations for the Therma Bright team to secure efficient and smooth delivery of CoviSafe™ to our global customers. Mr. Levine's experience in global...
2021-01-15 6:30 AM EST
Therma Bright Signs IR Agreement with Barwicki Investor Relations, Adds $300,000 to Treasury Through Exercise of Warrants and Options; and Grants Options
Toronto, Ontario--(Newsfile Corp. - December 24, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, announces that it has engaged Barwicki Investor Relations to provide investor relations services to the Company. Founded by Andrew Barwicki in 2006, Barwicki Investor Relations is a full service investor relations firm representing publicly traded companies and pre-IPO companies. Andrew Barwicki has 25+ years experience in...
2020-12-24 6:39 AM EST
Therma Bright Achieves High Accuracy Results from Feasibility Studies for Its COVID-19 Rapid Saliva Test, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - December 7, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the preliminary results achieved during the feasibility studies indicate a test sensitivity of 80% and a specificity of over 90% for Therma's CoviSafe™ rapid test for detecting SARS-CoV-2 in saliva. Therma entered into an agreement with nanoComposix, a developer and manufacturer of rapid diagnostic tests to...
2020-12-07 5:07 PM EST
Therma Bright gründet neues Unternehmen namens Torion Biosciences zur Entwicklung seines COVID-19 Antigen-Schnelltests, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - Donnerstag, 5. November 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, gibt die Gründung eines neuen Unternehmens mit dem Namen Torion Biosciences Inc. ("Torion") bekannt, das der Entwicklung, Lizenzierung und Vermarktung eines Antigen-Schnelltests zum Screening symptomatischer sowie asymptomatischer COVID-19-Infizierter bzw. -Verdachtspersonen dienen soll. Therma Bright...
2020-11-05 4:18 PM EST
Therma Bright Creates New Venture, Torion Biosciences to Develop its COVID-19 Rapid Antigen Test, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - November 4, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it has created a new venture, called Torion Biosciences Inc. ("Torion") with a mandate to develop, license and commercialize a rapid antigen test for screening of both symptomatic and asymptomatic individuals, infected or suspected of being infected with the COVID-19 virus. Therma Bright will control 50% of...
2020-11-04 5:00 PM EST
Therma Bright and Orpheus Medica Advance CoviSafe(TM) Rapid Saliva Test to Formal Product Developmental Phase
Toronto, Ontario--(Newsfile Corp. - October 21, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce the successful completion of the initial feasibility studies with its polypeptide detection candidates for CoviSafe™. Therma & Orpheus are also pleased to announce the engagement of nanoComposix Inc. ("nanoComposix") to complete the...
2020-10-21 7:15 PM EDT
Therma Bright und Orpheus Medica sichern Mitacs-Finanzierung zur Unterstützung ihres Forschungs- und Entwicklungsprogramms für COVID-19
Toronto, Ontario--(Newsfile Corp. - Freitag, 9. Oktober 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, und sein Mitentwicklungspartner, Orpheus Medica Inc. ("Orpheus") freuen sich über die Bewilligung eines "Mitacs Elevate"-Forschungspraktikumsprogramms. Der Projektantrag unterlief eine Peer-Review. Ende September wurden Matching-Mittel für ein Postdoktorandenstipendium bewilligt. Therma und Orpheus führen derzeit...
2020-10-09 10:20 AM EDT
Therma Bright and Orpheus Medica Secure Mitacs Funding to Support Its COVID-19 Research and Development Program
Toronto, Ontario--(Newsfile Corp. - October 8, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce the recent award of a Mitacs Elevate research internship program . The project proposal has been peer-reviewed and approved in late September for matching funds for a Postdoctoral Fellowship. Therma and Orpheus are conducting feasibility...
2020-10-08 9:05 AM EDT
Therma Bright & Orpheus Medica to be Featured on BTV Business Television on BNN Bloomberg
Toronto, Ontario--(Newsfile Corp. - September 23, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce they will be appearing on National TV on Saturday September 26 and Sunday September 27, 2020. The interview will focus on Therma's products and CoviSafeTM, a rapid test for detecting SARS-CoV-2 in saliva. BTV-Business Television is Canada's...
2020-09-23 7:00 AM EDT
Therma Bright and Orpheus Provide Development Update for its COVID-19 Rapid Saliva Test, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - September 15, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to provide an update on the development progress of the CoviSafeTM rapid test for detecting SARS-CoV-2 in saliva. As announced on September 3, 2020, Orpheus identified a series of polypeptides for the screening and detection of the virus (SARS-CoV-2)...
2020-09-15 5:00 AM EDT
Therma Bright und Orpheus identifizieren neue biologische Nachweismoleküle für den COVID-19-Schnelltest
Toronto, Ontario--(Newsfile Corp. - Freitag, 4. September 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Technologieunternehmen für medizinische Geräte, freut sich bekannt zu geben, dass sein Entwicklungspartner Orpheus Medica Inc. ("Orpheus") eine Reihe von Polypeptiden für das Screening und den Nachweis des COVID-19 verursachenden Virus (SARS-CoV-2) identifiziert hat. Die von Orpheus und seinen akademischen Mitarbeitern durchgeführten...
2020-09-04 9:18 AM EDT
Therma Bright and Orpheus Identify Novel Biological Detection Molecules for COVID-19 Rapid Test
Toronto, Ontario--(Newsfile Corp. - September 3, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that its co-development partner, Orpheus Medica Inc. ("Orpheus") has identified a series of polypeptides for the screening and detection of the virus (SARS-CoV-2) causing COVID-19. The research carried out by Orpheus and its academic collaborators has resulted in several high-quality polypeptides that...
2020-09-03 8:58 AM EDT
Therma Bright Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - September 1, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, provides updates on the following: Further Testing of TherOZap® Technology Against the Dengue Virus; Redesign of InterceptCS™ Cold Sore Technology; Relaunch of BenePod® and Venowave® products; Joint development with Orpheus - CoviSafe™. Therma Bright Plans Further Testing of TherOZap® Technology Against the Dengue Virus As...
2020-09-01 9:25 AM EDT
Therma Bright schließt eine Vereinbarung mit Orpheus zur gemeinsamen Entwicklung des COVID-19 Speichel-Schnelltests von Orpheus Medica, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - Freitag, 28. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, freut sich bekannt zu geben, eine endgültige Vereinbarung zur gemeinsamen Entwicklung mit Orpheus Medica Inc. ("Orpheus") oder (Therma & Orpheus, die "Parteien") unterzeichnet zu haben. Diese Vereinbarung eröffnet Therma Zugang zu der neuen biologischen Plattform von Orpheus und ermöglicht die gemeinsame Entwicklung...
2020-08-28 9:01 AM EDT
Therma Bright Enters into Co-Development Agreement with Orpheus Medica's COVID-19 Rapid Saliva Test, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - August 27, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has signed a co-development definitive agreement with Orpheus Medica Inc. ("Orpheus") or (Therma & Orpheus, the "Parties"). This agreement will allow Therma access to Orpheus' novel biological platform and the joint development of a rapid saliva test for the screening and detection of the virus...
2020-08-27 9:07 AM EDT
Therma Bright Acquires Benepod(R) Pain Relief Technology and Other Innovative Medical Device Technology from Saringer Life Science Technologies Inc.
Toronto, Ontario--(Newsfile Corp. - August 26, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that it has closed the transaction to acquire Benepod® pain relief technology and other innovative medical device technology from Saringer Life Science Technologies Inc. ("Saringer" or "SLST Inc."). After completion of final negotiations, Therma acquired the Saringer assets in an all cash transaction...
2020-08-26 5:00 AM EDT
Update von Therma Bright zu den Transaktionen Saringer und Orpheus
Toronto, Ontario--(Newsfile Corp. - Donnerstag, 20. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizingeräteunternehmen, gibt hiermit ein Update in Erwiderung auf Anfragen von Aktionären. Saringer - Akquise von Vermögenswerten (Benepod®-Schmerzlinderungstechnologie) Wie bereits zuvor angekündigt (siehe Pressemitteilungen vom 15. Januar, 8. April und 9. Juli 2020), hat Therma eine zufriedenstellende Due Diligence-Prüfung...
2020-08-20 4:17 PM EDT